Overview
Cowpox virus (CPXV) is a zoonotic orthopoxvirus that primarily affects humans and animals through contact with infected rodents or other contaminated animals. Historically associated with infections in dairy workers due to contact with infected cows, contemporary cases often arise from interactions with domestic pets like rats and cats, as well as zoo animals. The epidemiology of CPXV has seen notable fluctuations, with reported increases in Europe highlighting the evolving nature of its transmission dynamics [PMID:34352194]. In susceptible populations, particularly small animals (SACs), CPXV can manifest with varying severity, ranging from mild, localized skin lesions to severe, systemic infections that can be life-threatening. Understanding the epidemiology, clinical presentation, diagnosis, and management of CPXV is crucial for effective prevention and treatment strategies.
Epidemiology
CPXV transmission predominantly occurs through direct contact with infected animals, with wild rodents such as bank voles, common voles, and striped field mice serving as key reservoir hosts [PMID:32093320]. These rodents shed the virus in their secretions and excretions, facilitating indirect transmission to humans and other animals through contaminated environments or fomites. In recent years, there has been a notable increase in reported cases in Europe, suggesting potential changes in ecological interactions or heightened awareness and reporting [PMID:34352194]. Domestic settings, particularly those involving pet rats and cats, have emerged as significant sources of human infection, underscoring the importance of hygiene practices and biosecurity measures in households with such pets. The sporadic nature of CPXV infections in small animals (SACs) emphasizes the need for continuous surveillance and preventive measures to mitigate outbreaks, especially in environments where these animals are housed in close proximity.
Clinical Presentation
The clinical manifestations of CPXV infection vary widely depending on the host and the route of exposure. In humans, a case study involving a pregnant woman exemplifies severe presentations, characterized by multiple hand lesions, fever, lymphadenopathy, and tragically, fetal demise due to congenital infection [PMID:34352194]. This underscores the potential for significant morbidity and mortality, particularly in immunocompromised or pregnant individuals. In SACs, CPXV infections typically present in two primary forms: mild, self-limiting conditions marked by localized skin lesions such as pustules and crusts, and severe, systemic infections that can be fatal. Severe cases often involve multifocal to diffuse skin lesions and evidence of viral replication beyond the skin, affecting other organs and leading to systemic complications [PMID:32093320]. The variability in clinical presentation necessitates a high index of suspicion for CPXV in patients with compatible symptoms following potential exposure to infected animals.
Diagnosis
Diagnosing CPXV infection relies heavily on molecular techniques due to the nonspecific nature of clinical symptoms. Polymerase Chain Reaction (PCR) analysis of biopsy samples from skin lesions remains the gold standard for confirming CPXV infection [PMID:34352194]. In clinical practice, PCR can detect viral DNA directly from cutaneous lesions, providing rapid and definitive diagnosis. Additionally, in cases involving pregnant women or suspected vertical transmission, comprehensive sampling including fetal, placental, and cutaneous tissues is essential to confirm congenital infection and assess the extent of viral dissemination [PMID:34352194]. Serological tests, while useful for epidemiological studies, are less reliable for acute diagnosis due to potential cross-reactivity with other orthopoxviruses. Therefore, PCR-based methods are prioritized for timely and accurate identification of CPXV infections.
Management
Currently, there is no specific antiviral therapy approved for the treatment of CPXV infections in humans or animals. Management strategies primarily focus on supportive care and infection control measures to prevent complications and secondary infections [PMID:32093320]. For patients with localized lesions, wound care, including proper cleansing and dressing changes, is crucial to prevent secondary bacterial infections. In severe cases, hospitalization may be necessary to manage systemic symptoms such as fever and organ involvement. Prophylactic measures are paramount in preventing CPXV infections, particularly in high-risk populations like pregnant women and SACs. Vaccination with modified vaccinia virus Ankara (MVA) has shown promise as a preventive strategy, offering cross-protection against orthopoxviruses, including CPXV [PMID:32093320]. Implementing strict biosecurity protocols in environments where susceptible animals are housed, such as zoos and pet facilities, is essential to minimize exposure risks.
Complications
CPXV infections can lead to a range of serious complications, particularly in vulnerable populations. The case of a pregnant woman highlights the severe risks associated with congenital CPXV infection, including fetal demise due to vertical transmission [PMID:34352194]. In adults, complications may include secondary bacterial infections of skin lesions, systemic spread leading to organ dysfunction, and in extreme cases, death. For SACs, severe generalized infections can result in significant morbidity and mortality, often due to multifocal skin lesions and systemic viral replication affecting multiple organ systems [PMID:32093320]. These complications underscore the necessity for early diagnosis and aggressive supportive care to mitigate adverse outcomes.
Special Populations
Pregnant women and small animals (SACs) represent particularly vulnerable groups in CPXV infection scenarios. Pregnant women face heightened risks due to the potential for vertical transmission, which can lead to severe fetal complications, as evidenced by reports of fetal demise following maternal infection [PMID:34352194]. Clinicians must maintain heightened vigilance in monitoring pregnant patients with suspected CPXV exposure, employing rigorous diagnostic protocols and close fetal surveillance. For SACs, the sporadic yet potentially severe nature of CPXV infections necessitates stringent preventive measures. These animals, often housed in controlled environments like zoos or specialized breeding facilities, are highly susceptible to outbreaks due to their confined living conditions and close interactions. Prophylactic vaccination strategies, such as those utilizing MVA, are critical in these settings to safeguard valuable and vulnerable populations [PMID:32093320]. Enhanced biosecurity practices, including regular health screenings and strict hygiene protocols, are essential to prevent the spread and mitigate the impact of CPXV infections in these special populations.
Key Recommendations
References
1 Ferrier A, Frenois-Veyrat G, Schvoerer E, Henard S, Jarjaval F, Drouet I et al.. Fatal Cowpox Virus Infection in Human Fetus, France, 2017. Emerging infectious diseases 2021. link 2 Prkno A, Hoffmann D, Kaiser M, Goerigk D, Pfeffer M, Winter K et al.. Field Trial Vaccination against Cowpox in Two Alpaca Herds. Viruses 2020. link
2 papers cited of 3 indexed.